“…It was significantly reduced in those infants who later developed severe ROP requiring treatment, compared to those who never developed any ROP. This result, in accordance with previous studies 11 – 15 , 25 , 26 , suggests that early platelet count, among the routinely performed blood parameters, may help to detect, far in advance, those infants who may be more prone to ROP worsening. More specifically, our study demonstrated that there was a trend of reduction of platelet count from noROP group to Group 2 and Group 1 ROP.…”
Section: Discussionsupporting
confidence: 91%
“…Therefore, our study analyzed the earliest blood test parameters in order to avoid these confounding factors. Moreover, our population was higher in number compared to other studies 11 – 13 . Our data demonstrated that premature infants developing severe ROP needing treatment are significantly smaller for GA and BW than noROP infants, confirming the importance of these parameters as main drivers of ROP.…”
Section: Discussioncontrasting
confidence: 56%
“…Therefore, most studies have been conducted on animal models, using oxygen-induced retinopathy 23 , 24 . However, in the last years, the need to improve the management of this potentially blinding disease has led several Authors to investigate in vivo the possible correlations between routinely tested blood parameters and ROPoutcome 11 – 15 . Specifically, these authors have shown that a reduced platelet count and thrombocytopenia (platelets < 100 × 10 9 /l or < 15010 9 /l) was correlated to severe ROP development 11 – 15 , suggesting a possible role of platelets in the pathogenesis and clinical course of ROP.…”
Pathophysiology of retinopathy of prematurity (ROP) still presents a gap. Lately blood tests parameters of premature infants have been measured at different times of ROP, attempting to detect correlations with ROP development and progression. So far, very early post-natal biomarkers, predictive of ROP outcome, have not been detected. Our purpose is to evaluate, in the earliest post birth blood sample, the correlation between routinely dosed blood parameters and ROP outcome. 563 preterm babies, screened according to ROP guidelines, were included and classified in conformity with ET-ROP study in “Group 1” (ROP needing treatment), “Group 2” (ROP spontaneously regressed) and “noROP” group (never developed ROP). The earliest (within an hour after delivery) blood test parameters routinely dosed in each preterm infant were collected. Platelet count was decreased in Group 1 versus noROP group (p = 0.0416) and in Group 2 versus noROP group (p = 0.1093). The difference of thrombocytopenic infants among groups was statistically significant (p = 0.0071). CRP was higher in noROP versus all ROPs (p = 0.0331). First post-natal blood sample revealed a significant thrombocytopenia in ROP needing treatment, suggesting a role of platelets in the pathophysiology and progression of ROP, possibly considering it as a predictive parameter of ROP evolution.
“…It was significantly reduced in those infants who later developed severe ROP requiring treatment, compared to those who never developed any ROP. This result, in accordance with previous studies 11 – 15 , 25 , 26 , suggests that early platelet count, among the routinely performed blood parameters, may help to detect, far in advance, those infants who may be more prone to ROP worsening. More specifically, our study demonstrated that there was a trend of reduction of platelet count from noROP group to Group 2 and Group 1 ROP.…”
Section: Discussionsupporting
confidence: 91%
“…Therefore, our study analyzed the earliest blood test parameters in order to avoid these confounding factors. Moreover, our population was higher in number compared to other studies 11 – 13 . Our data demonstrated that premature infants developing severe ROP needing treatment are significantly smaller for GA and BW than noROP infants, confirming the importance of these parameters as main drivers of ROP.…”
Section: Discussioncontrasting
confidence: 56%
“…Therefore, most studies have been conducted on animal models, using oxygen-induced retinopathy 23 , 24 . However, in the last years, the need to improve the management of this potentially blinding disease has led several Authors to investigate in vivo the possible correlations between routinely tested blood parameters and ROPoutcome 11 – 15 . Specifically, these authors have shown that a reduced platelet count and thrombocytopenia (platelets < 100 × 10 9 /l or < 15010 9 /l) was correlated to severe ROP development 11 – 15 , suggesting a possible role of platelets in the pathogenesis and clinical course of ROP.…”
Pathophysiology of retinopathy of prematurity (ROP) still presents a gap. Lately blood tests parameters of premature infants have been measured at different times of ROP, attempting to detect correlations with ROP development and progression. So far, very early post-natal biomarkers, predictive of ROP outcome, have not been detected. Our purpose is to evaluate, in the earliest post birth blood sample, the correlation between routinely dosed blood parameters and ROP outcome. 563 preterm babies, screened according to ROP guidelines, were included and classified in conformity with ET-ROP study in “Group 1” (ROP needing treatment), “Group 2” (ROP spontaneously regressed) and “noROP” group (never developed ROP). The earliest (within an hour after delivery) blood test parameters routinely dosed in each preterm infant were collected. Platelet count was decreased in Group 1 versus noROP group (p = 0.0416) and in Group 2 versus noROP group (p = 0.1093). The difference of thrombocytopenic infants among groups was statistically significant (p = 0.0071). CRP was higher in noROP versus all ROPs (p = 0.0331). First post-natal blood sample revealed a significant thrombocytopenia in ROP needing treatment, suggesting a role of platelets in the pathophysiology and progression of ROP, possibly considering it as a predictive parameter of ROP evolution.
“…However, a possible association between RBC transfusions and an increased ROP risk remains a subject of controversy, as neither prospective [9-11] nor retrospective [12-14] data analyses have provided consistent, unambiguous results. Similarly, other studies have suggested links between thrombocytopenia, PLT transfusions, and ROP development [15-18]. Our aim was to investigate whether associations existed between RBC and PLT transfusions and ROP in Switzerland.…”
Section: Introductionmentioning
confidence: 85%
“…For instance, PLT transfusion release cytokines, VEGF and other immunomodulatory mediators, and favours inflammatory and proliferative processes [8]. Other studies have shown associations between severe thrombocytopenia and ROP development [15-18]. Thrombocytopenia in itself triggers the release of pro-inflammatory mediators [24].…”
<b><i>Aim:</i></b> The aim of this study is to examine possible associations between the transfusion of RBC or platelets (PLTs) and the development of retinopathy of prematurity (ROP) in infants. <b><i>Methods:</i></b> This retrospective, national, case-control study included all live births in Switzerland between 2013 and 2018. We investigated preterm infants at a gestational age of <28 weeks, who developed higher stage ROP (≥stage 2, <i>n</i> = 178). Each case infant was matched to another of the same sex who did not develop ROP (<i>n</i> = 178, control group). <b><i>Results:</i></b> When compared with the control group, we observed higher numbers of RBC transfusions per infant and higher percentages of infants receiving PLT transfusions in the case group. An adjusted logistic regression analysis revealed that both RBC (odds ratio [OR] 1.081, 95% confidence interval [CI] 1.020–1.146) and PLT transfusions (OR = 2.502, 95% CI 1.566–3.998) numbers were associated with ROP development. <b><i>Conclusions:</i></b> Multiple RBC and PLT transfusions are associated with higher stage ROP development. Prospective studies are required to determine their potential as risk factors.
Magnetic resonance imaging (MRI) of 7 T and higher can provide superior image resolution and capability. Clinical tests have been performed in 9.4 T MRI, and 21.1 T small‐bore‐size MRI has also been tested in rodents. Although the safety issue is a prerequisite for their future medical application, there are very few relevant studies for the safety of static magnetic fields (SMFs) of ≧20 T. The aim of this study was to assess the biological effects of 7.0–33.0 T SMFs in healthy adult mice. This was a prospective study, in which 104 healthy adult C57BL/6 mice were divided into control, sham control, and 7.0–33.0 T SMF‐exposed groups.The sham control group and SMF group were handled identically, except for the electric current for producing SMF. A separate control group was placed outside the magnet and their data were used as normal range. After 1 h exposure, all mice were routinely fed for another 2 months while their body weight and food/water consumption were monitored. After 2 months, their complete blood count, blood biochemistry, key organ weight, and histomorphology were examined. All data are normally distributed. Differences between the sham and SMF‐exposed groups were evaluated by unpaired t test. Most indicators did not show statistically significant changes or were still within the normal ranges, with only a few exceptions. For example, mono % in Group 2 (11.1 T) is 6.03 ± 1.43% while the normal range is 6.60–9.90% (p < 0.05). The cholesterol level in 33 T group is 3.38 ± 0.36 mmol/L while the normal range is 2.48–3.29 mmol/L (p < 0.05). The high‐density lipoprotein cholesterol level in 33 T group is 2.54 ± 0.29 mmol/L while the normal reference range is 1.89–2.43 mmol/L (p < 0.01). Exposure to 7.0–33.0 T for 1 h did not have detrimental effects on normal adult mice.
Level of Evidence
1
Technical Efficacy Stage
1
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.